The US Food and Drug Administration has approved Pembrolizumab for adjuvant treatment following resection and platinum-based chemotherapy in patients with NSCLC (non-small cell lung cancer). This approval has been based on the…
Category: Lung Cancer Drugs
Get an ideas about the lung cancer treatment drugs, here we provide only information about drugs not to advice them to take without proper doctor guideline. For information about lung cancer drugs browse.
U.S. FDA Approves Lung Cancer Drug, Adagrasib
The US Food and Drug Administration (FDA) has granted accelerated approval for Mirati Therapeutics’ Krazati (adagrasib) for treatment of mutated locally advanced or metastatic non-small cell lung cancer in adults. This accelerated…
FDA Grants Approval to Trastuzumab Deruxtecan for HER2 Lung Cancer
Lung cancer patients now have another treatment option. For those tumors carrying HER2 mutations, can now be treated with trastuzumab deruxtecan. This drug is already approved for use in HER2-positive breast cancer…
FDA Approves FoundationOne CDx in Non-Small Cell Lung Cancer
U.S. Food and Drug Administration (FDA) has approved the FoundationOne CDx as a companion diagnostic to guide treatment selection for patients with non-small cell lung cancer. This approval applies to the use…
FDA Approves Nivolumab Plus Chemo as Neoadjuvant Therapy for NSCLC Treatment
The FDA has approved nivolumab plus platinum-doublet chemotherapy for patients with non-small cell lung cancer in the neoadjuvant setting. Nivolumab is the first immune checkpoint inhibitor to get approval for resectable NSCLC….
European Commission Approves Pfizer’s Lorviqua for Advanced Lung Cancer Treatment
European Commission (EC) has granted marketing authorization for Lorviqua as monotherapy for treatment of patients with anaplastic lymphoma kinase (ALK) – positive advanced non-small cell lung cancer. Lorviqua is approved in US…
US FDA Approves Roche’s Tecentriq as Adjuvant Treatment for Early NSCLC
The US Food and Drug Administration (FDA) has approved Roche’s Tecentriq or atezolizumab as adjuvant treatment for patients with Stage II-IIIA non-small cell lung cancer (NSCLC) whose tumors express PD-L1=1%, as determined…
Takeda’s Exkivity Approved by FDA for Rare form of Lung Cancer
Takeda Pharmaceutical Co. Ltd. becomes the first one to get FDA approval for an oral drug targeted against rare form of non-small cell lung cancer. FDA has approved Exkivity (mobocertinib) for treatment…